A recent study has raised concerns about two widely used classes of drugs for Type 2 diabetes, sulfonylureas and basal insulin, suggesting they may be associated with a higher risk of cardiovascular events. These medications, often prescribed after metformin proves insufficient, could potentially lead to serious harm, prompting a call for a shift in treatment strategies.
Key Takeaways
- Two common Type 2 diabetes medications, sulfonylureas and basal insulin, are linked to increased cardiovascular risks.
- Patients taking these drugs are more likely to experience heart attacks, strokes, heart failure, or amputations compared to those on newer drug classes.
- The findings suggest a need for a paradigm shift in how Type 2 diabetes is treated, prioritizing newer medications with better cardiovascular profiles.
Increased Cardiovascular Risk Identified
A significant study published in JAMA Network Open has identified a potential link between sulfonylureas and basal insulin, commonly prescribed second-line treatments for Type 2 diabetes, and an elevated risk of cardiovascular events. These events can include heart attack, stroke, heart failure, and even amputation. The research indicates that patients on sulfonylureas are 36% more likely, and those on basal insulin are twice as likely, to suffer such harm compared to individuals using newer medications like DPP-4 inhibitors.
A Call for a Paradigm Shift in Treatment
Matthew O’Brien, MD, lead author of the study and assistant professor at Northwestern University Feinberg School of Medicine, emphasized the critical need for patients and healthcare providers to be aware of these risks. “People should know if the medications they’re taking to treat their diabetes could lead to serious cardiovascular harm,” O’Brien stated. “This calls for a paradigm shift in the treatment of Type 2 diabetes.”
The study highlights that over 60% of patients requiring a second-line diabetes medication are prescribed either sulfonylureas or basal insulin. The implications are staggering, with calculations suggesting that for every 37 people treated with basal insulin over two years, one cardiovascular event could be observed. For sulfonylureas, this number rises to 103 people.
Exploring Alternative Treatments
Researchers suggest that physicians should more routinely consider prescribing newer classes of antidiabetic medications after metformin. These include GLP-1 agonists (e.g., liraglutide), SGLT-2 inhibitors (e.g., empagliflozin), and DPP-4 inhibitors (e.g., sitagliptin). While these newer drugs are more expensive than sulfonylureas, their more favorable cardiovascular profiles may offer a safer long-term treatment option.
Understanding Sulfonylureas’ Mechanism
Further research from the University of Barcelona suggests that sulfonylureas might not only increase cardiovascular risk but could also potentially worsen the progression of Type 2 diabetes itself. These drugs, used since the 1950s, work by stimulating insulin secretion from pancreatic beta cells. However, new findings indicate that prolonged exposure to sulfonylureas may cause these beta cells to lose their functional identity and impair their ability to produce and secrete insulin effectively. This could explain the declining effectiveness of sulfonylureas over time and their potential contribution to disease progression.
Sources
- Two Type 2 Diabetes Drugs Linked to Higher Risk of Heart Disease, Northwestern University.
- One of the Most Common Diabetes Treatments May Be Making the Disease Worse, Study Warns, SciTechDaily.